person · Reporting owner
EcoR1 Capital Fund Qualified, L.P.
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | 10% owner | April 17, 2018 | April 18, 2018 |
| Kura Oncology, Inc.KURA · Entity 4871 | 10% owner | December 17, 2018 | January 10, 2019 |
| Nuvation Bio Inc.NUVB · Entity 4384 | Director | September 19, 2023 | September 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date April 17, 2018 · Filed April 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Call OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $60.00 · Expires 2018-11-16 | Direct | 1,213 |
Reported balance
After 2018-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-17 · Purchase · Acquired 246 · Balance 1,213 |
Kura Oncology, Inc.
Report date December 17, 2018 · Filed January 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,408,097 |
Ending reported balance
After 2018-12-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-12-17 · Sale · Disposed 26,520 · Balance 4,194,209 Row 2 · 2018-12-18 · Purchase · Acquired 78,469 · Balance 4,272,678 Row 3 · 2018-12-19 · Purchase · Acquired 51,879 · Balance 4,324,557 Row 4 · 2018-12-21 · Purchase · Acquired 83,540 · Balance 4,408,097 |
Nuvation Bio Inc.
Report date September 19, 2023 · Filed September 22, 2023 · Amendment
Jointly reported with NODELMAN OLEG, EcoR1 Capital, LLC, EcoR1 Capital Fund, L.P., EcoR1 Venture Opportunity Fund, LP, Biotech Opportunity GP, LLC
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee Notes | 12,674,775 |
Last balance in matching sequence
After 2023-09-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-09-19 · Purchase · Acquired 5,143,000 · Balance 12,504,675 F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 2 · 2023-09-20 · Purchase · Acquired 117,100 · Balance 12,621,775 F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. Row 3 · 2023-09-21 · Purchase · Acquired 53,000 · Balance 12,674,775 F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023. F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F2: Qualified Fund is the record holder of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F2: Qualified Fund is the record holder of these securities.
F3: On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023.
F4: The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023.
F5: Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Panacea Acquisition Corp. II
Report date April 28, 2023 · Filed May 02, 2023
Jointly reported with EcoR1 Panacea Holdings II, LLC, EcoR1 Capital Fund, L.P., EcoR1 Venture Opportunity Fund, LP, EcoR1 Capital, LLC, Biotech Opportunity GP, LLC, NODELMAN OLEG
Section 16 reporting ended · disclosed 2023-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-04-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-04-28 · Disposition to issuer · Disposed 545,000 · Balance 0 F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023. F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 10, 2023, Panacea Acquisition Corp. II (the "Company") announced that it did not consummate an initial business combination by April 9, 2023, the deadline under its Amended and Restated Memorandum and Articles of Association. In connection with the winding up of the Company, the Class A ordinary shares, par value $0.0001 per share, held by the Reporting Persons were surrendered for no consideration on April 28, 2023.
F2: The reporting owner, EcoR1 Panacea Holdings II, LLC (the "Sponsor"), in whose name the securities reported herein were held, is managed by its managing members, EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. and EcoR1 Venture Opportunity Fund, L.P. The general partner of EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. is EcoR1 Capital, LLC and the general partner of EcoR1 Venture Opportunity Fund, L.P. is Biotech Opportunity GP, LLC (together with EcoR1 Capital, LLC, the "General Partners"). Oleg Nodelman is the manager of each of the General Partners. Each of the Reporting Persons may have been deemed to be a beneficial owner of the shares held by the Sponsor but each (other than the Sponsor) disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.
aTYR PHARMA INC
Report date May 14, 2018 · Filed May 16, 2018
Section 16 reporting ended · disclosed 2018-05-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-05-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-05-14 · Sale · Disposed 354,791 · Balance 2,854,525 Row 2 · 2018-05-15 · Sale · Disposed 121,294 · Balance 2,733,231 Row 3 · 2018-05-16 · Sale · Disposed 2,733,231 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2017 Filed Dec 14, 2017 20:46 UTC | aTYR PHARMA INC ATYR · Entity 7233 | SaleCommon Stock | 1,070 | $4.30 | $4,601.00 |
DisclosureSEC source: 0001140361-17-046221 · doc1.xml · nonDerivative · entry 3 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,222,078 Read SEC document |
| November 01, 2017 Filed Dec 14, 2017 20:46 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 24,728 | $4.80 | $118,694.40 |
DisclosureSEC source: 0001140361-17-046221 · doc1.xml · nonDerivative · entry 2 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,223,148 Read SEC document |
| October 01, 2017 Filed Dec 14, 2017 20:46 UTC | aTYR PHARMA INC ATYR · Entity 7233 | PurchaseCommon Stock | 4,879 | $5.05 | $24,638.95 |
DisclosureSEC source: 0001140361-17-046221 · doc1.xml · nonDerivative · entry 1 EcoR1 Capital Fund Qualified, L.P. · CIK 0001598292 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,198,420 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.